Literature DB >> 9549805

Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer.

G M Kiebert1, D Curran, N K Aaronson.   

Abstract

For more than 30 years the European Organization for Research and Treatment for Cancer (EORTC) has conducted, co-ordinated, and stimulated research on the experimental and clinical bases of treatment of cancer and related problems. For more than a decade the EORTC has included quality of life as an outcome measure in some of its trials. The number of clinical studies that include QOL as an evaluation endpoint has increased rapidly in the last few years, and is still increasing steadily. This necessitated a careful and critical evaluation of procedures and results so far in order to generate appropriate guidelines and procedures for incorporating QOL issues in all stages of the clinical trial process, including protocol writing, data collection, data analysis, and reporting of results. This paper provides an overview of the types and the design of studies, data management of quality of life assessment, compliance, missing data and lessons learned during the past years with respect to QOL assessments in the EORTC studies.

Entities:  

Mesh:

Year:  1998        PMID: 9549805     DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<561::aid-sim803>3.0.co;2-s

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults.

Authors:  M E Ford; S L Havstad; C S Kart
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Proxy ratings of health related quality of life in patients with hepatocellular carcinoma.

Authors:  Jennifer L Steel; David A Geller; Brian I Carr
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

3.  Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.

Authors:  E Charton; B Cuer; F Cottone; F Efficace; C Touraine; Z Hamidou; F Fiteni; F Bonnetain; M-C Woronoff-Lemsi; C Bascoul-Mollevi; A Anota
Journal:  Qual Life Res       Date:  2019-11-27       Impact factor: 4.147

4.  Beyond efficacy and effectiveness: conducting economic analyses during clinical trials.

Authors:  Teresa M Waters; Jeri A Logemann; Barbara Roa Pauloski; Alfred W Rademaker; Cathy L Lazarus; Lisa A Newman; Annette K Hamner
Journal:  Dysphagia       Date:  2004       Impact factor: 3.438

5.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

6.  Problems eliciting cues in SEIQoL-DW: quality of life areas in small-cell lung cancer patients.

Authors:  Marjan Westerman; Tony Hak; Anne-Mei The; Harry Groen; Gerrit van der Wal
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

7.  Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.

Authors:  M Walker; J Brown; K Brown; A Gregor; I R Whittle; R Grant
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

8.  Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.

Authors:  Louis Garnier; Emilie Charton; Antoine Falcoz; Sophie Paget-Bailly; Dewi Vernerey; Marine Jary; François Ducray; Elsa Curtit
Journal:  Neurooncol Pract       Date:  2020-11-11

9.  Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus).

Authors:  Linda E Carlson; Barry D Bultz; Donald G Morris
Journal:  Health Qual Life Outcomes       Date:  2005-01-27       Impact factor: 3.186

Review 10.  Patient reported outcomes (PROs) in clinical trials: is 'in-trial' guidance lacking? a systematic review.

Authors:  Derek G Kyte; Heather Draper; Jonathan Ives; Clive Liles; Adrian Gheorghe; Melanie Calvert
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.